StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
January 3, 2019 3:59 PM
RBC Capital analyst Brian Abrahams said today's Bristol-Myers Squibb (NYSE: BMY) takeover of Celgene (NASDAQ: CELG) likely kicks off a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Rumors
Trader Talk
Next Articles
SAGE Therapeutics (SAGE) Reports SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
January 7, 2019 6:01 AM
Vertex Pharma (VRTX) Expands Current Partnership with X-Chem Inc.
January 4, 2019 8:17 AM
Biogen (BIIB) Reports Strategic Collaboration with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
January 4, 2019 7:32 AM
Biogen (BIIB) Reports Strategic Collaboration with C4 Therapeutics to Discover and Develop Potential New Treatments for Neurological Conditions
January 4, 2019 7:31 AM